NUVL (nuvalent.com) מקדם שווי פעילות להכנסות

סמלים רשמיים של חברת Nuvalent Inc (NUVL)

Nuvalent, Inc. (NUVL) optimizes drug discovery through AI modeling, which contrasts with planned research capital expenditures despite maintaining a robust cash reserve. The company's EV/Sales ratio reflects valuation dynamics, with the current level sitting around 0.00. The business's potential revenue relies on future successes in the therapy of non-small cell lung cancer and other complex pathologies.

nuvalent.com (NUVL): מכפיל EV/Sales מ-23.11.2025 עד 25.07.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Nuvalent (NUVL)

- מחיר ותחזית קונצנזוס למחירים:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית של החברה:Nuvalent, Inc. NUVL
דוגמת מוצר של nuvalent.com

This indicator serves as a stress-testing tool for asset values, allowing for the identification of anomalies in the market valuation of a business. The metric compares the total enterprise value, excluding the impact of debt, against annual turnover; however, the price-to-sales ratio for Nuvalent, Inc. (NUVL) reflects only speculative expectations, as the absence of commercial sales renders the calculation purely nominal against a backdrop of capital burn.